<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> and Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> are associated with abnormal regulation of <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> metabolism that are highlighted by clinical similarities between the sequelae of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:e sem="disease" ids="C0010481" disease_type="Disease or Syndrome" abbrv="">Cushing's syndrome</z:e>, as well as <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi>' functional antagonism to insulin </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="35346">11beta-hydroxysteroid</z:chebi> dehydrogenase type 1 (11beta-HSD1) activates functionally inert <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> precursors (<z:chebi fb="11" ids="16962">cortisone</z:chebi>) to active <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> (<z:chebi fb="1" ids="17650">cortisol</z:chebi>) within insulin target tissues, such as adipose tissue, thereby regulating local <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> action </plain></SENT>
<SENT sid="2" pm="."><plain>Recent data, mainly from rodents, provide considerable evidence for a causal role of 11beta-HSD1 for the development of visceral <z:hpo ids='HP_0001513'>obesity</z:hpo> and Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> though data in humans are not unequivocal </plain></SENT>
<SENT sid="3" pm="."><plain>This review summarizes current evidence on a possible role of 11beta-HSD1 for development of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, raising the possibility of novel therapeutic options for the treatment of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by inhibition or down-regulation of 11beta-HSD1 activity </plain></SENT>
</text></document>